Scope 3 emissions recalculated for 2021-2024 after Quantis tool discontinuation In 2024 DFE Pharma recalculated Scope 3 emissions for 2021-2024 using more specific data sources. 94% now based on supplier-specific amount-based data (80% from farm-level lactose supplier data), 4% industry averages, 2% financial proxies. GHG emissions ~3% lower than previously reported.
▾ expand
2021-2023 GHG data restated Data for Scope 1, 2 and 3 emissions for 2021-2023 were recalculated in 2024 after discontinuation of Quantis tool in 2023. Methodology changed from database/spend-based to more granular supplier-specific data.
▾ expand
EcoVadis Gold Medal (Top 5%) May 2024 DFE Pharma awarded EcoVadis Gold Medal in May 2024, positioning the company in the top 5% of all rated companies worldwide. Previously held Silver Medal in 2023.
▾ expand
All EU sites running on 100% green electricity In 2024 all EU sites operated on 100% green electricity. Renewable energy usage nearly doubled (67k→143k GJ) primarily due to biomass boiler commissioning at new MCC plant in Cuddalore, India.
▾ expand
Zero deforestation by Dec 31, 2025 DFE Pharma aims to achieve zero deforestation across all primary deforestation-linked commodities by December 31, 2025.
▾ expand
Fully recyclable packaging by 2030 + 25% plastic reduction Goal to ensure all packaging materials used in operations are 100% recyclable by 2030, with 25% reduction in plastic use by 2030.
▾ expand
Biodiversity Rating process for suppliers launched DFE Pharma launched a Biodiversity Rating process evaluating suppliers on deforestation prevention, biodiversity conservation, and animal health/welfare. 49% of revenue-based supplier volume evaluated; FLAG suppliers prioritized.
▾ expand
Living wage commitment across 13 global locations Global analysis on living wage completed in 2024; committed to pay above 'Fair Wage' defined living wage at all 13 global locations.
▾ expand
Reporting consolidated into Royal FrieslandCampina CSRD framework In 2024, DFE Pharma's reporting was consolidated into Royal Friesland Campina's framework for CSRD compliance, while broader sustainability reporting continues independently.
▾ expand
No use of offsets/removals — direct abatement only DFE Pharma is aiming to prioritize emissions reduction through direct abatement, rather than using carbon credits. The firm plans to avoid the use of offsets to achieve 2030 reduction targets. Has invested in carbon-credit-sourced renewable energy projects in the interim until sufficient renewable sources are available. No removals (DAC, BECCS, etc.) disclosed.
▾ expand
see 22 more events →